| Symbol | PHVS |
|---|---|
| Name | PHARVARIS N.V. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | EMMY NOETHERWEG 2, LEIDEN, 2333 BK, Netherlands |
| Telephone | +31 712036410 |
| Fax | — |
| — | |
| Website | https://www.pharvaris.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001830487 |
| Description | Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. Additional info from NASDAQ: |
Modig Berndt 🔴 sold 2.3K shares of Pharvaris N.V. (PHVS) at $31.46 Transaction Date: Jun 17, 2026 | Filing ID: 274440
Read moreLu Peng 🔴 sold 117 shares of Pharvaris N.V. (PHVS) at $32.20 Transaction Date: Jun 12, 2026 | Filing ID: 272978
Read moreLu Peng 🔴 sold 109 shares of Pharvaris N.V. (PHVS) at $31.51 Transaction Date: Jun 11, 2026 | Filing ID: 271314
Read more📋 Berndt B.A.E. Modig (Director) plans to sell 2K shares of Pharvaris N.V. (at $30.72 each, total $70K) Filed: Jun 15, 2026 | ID: 006130
Read moreData Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
Read moreNijdam Anna 🔴 sold 2.7K shares of Pharvaris N.V. (PHVS) at $30.87 Transaction Date: Jun 04, 2026 | Filing ID: 261316
Read more📋 ANNA NIJDAM (Officer) plans to sell 3K shares of PHARVARIS N.V. (at $30.87 each, total $82K) Filed: Jun 04, 2026 | ID: 005678
Read moreMonges Viviane 🔴 sold 9.7K shares of Pharvaris N.V. (PHVS) at $30.29 Transaction Date: May 21, 2026 | Filing ID: 239754
Read more